Kalydeco Approved in Europe to Treat Children With R117H Mutation

Home Forums CF Science and Research Kalydeco Approved in Europe to Treat Children With R117H Mutation
  • This topic is empty.
Viewing 0 reply threads
  • Author
    Posts
    • June 16, 2020 at 9:44 am #15187
      Cystic Fibrosis News Moderator

        The European Commission has approved Kalydeco (ivacaftor) to treat children and adolescents with CF who carry the R117H mutation in the CFTR gene. Read more here.

        What do you think of this news?

    • Author
      Posts
    Viewing 0 reply threads
    • You must be logged in to reply to this topic.

    Forums search

    Generic selectors
    Exact matches only
    Search in title
    Search in content
    Post Type Selectors
    Search in posts
    Search in pages

    Who’s Online

    There are no users currently online

    Members

    BioNews, Inc.

    3 W Garden St
    Suite 700
    Pensacola, FL 32502
    Website: bionews.com
    Email: [email protected]
    Phone: 1-800-936-1363

    Disclaimer

    This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

    Copyright © 2017-2023 All rights reserved.

    ©[current-year] KLEO Template a premium and multipurpose theme from Seventh Queen